The objective of this trial is to study the management of PPE in participants with metastatic ovarian or breast cancer treated with Caelyx, and determine the frequency of use of pharmacological treatment (preventive or therapeutic) for PPE and compliance of educational recommendations for PPE.
Study Type
OBSERVATIONAL
Enrollment
154
Number of Participants Who Received Concomitant Treatment Strategies to Manage Palmar-Plantar Erythrodysesthesia (PPE)
Participants treated with Caelyx who developed PPE and the categories of specific treatment strategies that were prescribed to manage the symptoms of PPE. Participants counted under the strategies: Keep Skin Hydrated; Avoid Sweating and Physical Activity; Avoid Tight-Fitting Clothing; Local Cooling of Hands and Feet; were those who either always or sometimes followed it.
Time frame: Participants will do a single visit, but cases will be collected during a period of 12 months.
Number of Participants That Received Curative Treatment and/or Prophylaxis Treatment for PPE
The number of participants who were treated with Caelyx, and who received either prophylactic treatment alone, or curative treatment alone, or both prophylactic and curative treatment for PPE.
Time frame: Participants will do a single visit, but cases will be collected during a period of 12 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.